Detalhe da pesquisa
1.
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
Breast Cancer Res
; 24(1): 71, 2022 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307826
2.
Subacute axial parkinsonism associated with anti-Ri antibodies.
Neurol Sci
; 42(3): 1155-1156, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822059
3.
Everolimus plus exemestane as first-line therapy in HRâº, HER2â» advanced breast cancer in BOLERO-2.
Breast Cancer Res Treat
; 143(3): 459-67, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362951
4.
Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study.
Haematologica
; 90(6): 858-60, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15951304
5.
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
Tumori
; 101(4): 398-403, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26045108
6.
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Curr Med Res Opin
; 29(11): 1463-73, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23962028
7.
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Cancer
; 104(7): 1428-33, 2005 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16116606
8.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Blood
; 104(10): 3052-7, 2004 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15265788